Lipoprotein(a): Apo-B Independent Atherogenesis and Inflammation-Dissociated Cardiovascular Risk
Year: 2026
Type: conference-abstract
Abstract: Background/Objectives: Despite widespread use of low-density lipoprotein cholesterol (LDL-C)-lowering therapies, substantial residual atherosclerotic cardiovascular disease (ASCVD) risk persists in primary care populations. Lipoprotein(a) [Lp(a)] is a common, genetically determined lipoprotein and is not routinely measured on standard lipid panels. Unlike LDL, Lp(a) contains an apolipoprotein(a) moiety with unique biological properties, including oxidized phospholipid transport, pro-inflammatory vascular signaling, and antifibrinolytic effects. This narrative literature review examines the hypothesis that Lp(a) represents a distinct, causal atherogenic lipoprotein with ASCVD risk independent of apolipoprotein B (apoB) and systemic inflammation. This review draws from cardiovascular prevention and risk stratification literature. No human subjects were involved.
Source: RVU Elevate
DOI: 10.82451/k51124
Authors: Kailani Jacobsen, Anoushka Singh, Benjamin Brooks
Institution: Rocky Vista University
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7171492444